《大行報告》瑞銀上調諾輝健康-B(06606.HK)目標價至52元 評級「買入」
諾輝健康-B(06606.HK)發盈喜,料去年收入總額將介乎2.05億至2.17億元人民幣,按年增長190.8%至207.8%。瑞銀因應盈喜以及預料國家藥監局最近批準諾輝健康的產品「幽幽管」註冊,將其目標價由48元上調至52元,維持「買入」評級。
瑞銀引述管理層指,將去年業績的強勁表現,歸因於更好的產品組合、高出廠價渠道表現出色。管理層預計幽幽管將於今日(18日)正式上線京東、天貓、美團等平臺,由於幽幽管的出廠價明顯高於現有產品「噗噗管」,公司有信心爲其未來帶來另一波增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.